This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Keryx Biopharmaceuticals Inc (KERX)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -111.52M -46.73M -22.72M -28.12M
Operating Gains/Losses 0.00 0.00 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 2.64M 0.00
(Increase) Decrease In Receivables -882.00K 0.00 7.00K -7.00K
(Increase) Decrease in Inventories -7.77M 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets -2.86M -802.00K 104.00K -334.00K
(Decrease) Increase In Payables 10.14M 6.79M -1.66M 3.82M
(Decrease) Increase In Other Current Liabilities 3.43M 497.00K -70.00K 0.00
(Increase) Decrease In Other Working Capital 498.00K -81.00K 12.00K -72.00K
Other Non-Cash Items 26.96M 5.95M -3.11M 1.85M
Net Cash From Continuing Operations -81.00M -34.32M -24.76M -22.82M
Net Cash From Discontinued Operations 0.00 0.00 0.00 1.00K
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -81.00M -34.32M -24.76M -22.82M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 38.26M 24.40M 15.47M 5.83M
Purchases of Property, Plant & Equipment -1.49M -346.00K -24.00K -57.00K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -49.77M -24.40M -11.26M -9.94M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -13.00M -346.00K 4.19M -4.17M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 120.11M 75.68M 0.00 33.83M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -7.53M 0.00 0.00 0.00
Net Cash From Financing Activities 112.59M 75.68M 0.00 33.83M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 18.59M 41.02M -20.57M 6.84M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

KERX Keryx Biopharmaceuticals Inc

Chart of KERX

Analysts Ratings for KERX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 4 4 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 1

KERX Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs